EC Number   |
Application |
Reference |
|---|
   3.5.1.15 | medicine |
diagnosis of Canavan disease, an autosomal recessive neurodegenerative disorder characterized by aspartoacylase deficiency, technique for prenatal diagnosis |
209005, 209006, 209007, 209008 |
| 3.5.1.15 | medicine |
mutations in the aspartoacylase aspA gene are implicated as the cause of Canavan Disease |
720476 |
| 3.5.1.15 | nutrition |
development of a general and simple procedure for the resolution of racemic amino acids |
288852 |
| 3.5.1.15 | pharmacology |
the enzyme is the taget for treatment of Canavan disease, enzyme replacement therapy can potentially be used to overcome these defects if a stable enzyme form that can gain access to the appropriate neural cells can be produced. PEGylated form of aspartoacylase are able to traverse the blood-brain barrier and show dramatic enhancement in brain tissue access and distribution, overview. Examination of the effect of enzyme administration on the immunological response |
734698 |
